Clinical Trial Update: Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for Ivonescimab (AK112) plus paclitaxel as second-line therapy in advanced gastric/gastroesophageal junction cancer; the study is not yet r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Ivonescimab (AK112) (ivonescimab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Gastric (Cardia, Body) Cancer | Phase 2 | Status: NOT_YET_RECRUITING